DeepMed Research

Bicalutamide

Generic Name: Bicalutamide

Brand Names: Casodex

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₁₄F_₄N_₂O_₄S

CAS Number: 90357-06-5

Unique Ingredient Identifier: A0Z3NAU9DP

Background: Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor.

Indication: Bicalutamide is indicated in combination with a luteinizing hormone-releasing hormone (LHRH) agonist for the treatment of Stage D2 metastatic carcinoma of the prostate.

Associated Conditions: Metastatic stage D2 Prostatic carcinoma

Clinical Trials

Trial to Promote Recovery From COVID-19 With Endocrine Therapy

Phase 2

Withdrawn

Conditions: SARS-CoV 2
COVID-19

Interventions: Drug: Bicalutamide 150 Mg Oral Tablet

First Posted Date: 2020-05-05

Last Posted Date: 2021-03-05

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Registration Number: NCT04374279

Locations: 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States

Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients

Phase 4

Conditions: Prostatic Neoplasms

Interventions: Drug: Leuprorelin
Drug: Goserelin
Drug: Triptorelin
Drug: Degarelix
Drug: Bicalutamide
Drug: Flutamide
Drug: Maximum androgen blockade

First Posted Date: 2020-01-30

Last Posted Date: 2021-07-29

Lead Sponsor: Wonju Severance Christian Hospital

Target Recruit Count: 164

Registration Number: NCT04248621

Locations: 🇰🇷
Department of Urology, Chonnam National University, School of Medicine, Gwangju, Korea, Republic of
🇰🇷
Department of Urology, Kyungpook National University, School of Medicine, Daegu, Korea, Republic of
🇰🇷
Department of Urology, Eulji University, College of Medicine, Daejeon, Korea, Republic of

and more 7 locations

A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan

Completed

Conditions: Prostatic Neoplasms

Interventions: Drug: Androgen-deprivation Therapy (ADT)
Drug: Bicalutamide
Drug: Abiraterone
Drug: Prednisolone
Drug: Docetaxel
Drug: Enzalutamide
Drug: Apalutamide

First Posted Date: 2019-07-26

Last Posted Date: 2025-04-25

Lead Sponsor: Janssen Pharmaceutical K.K.

Target Recruit Count: 979

Registration Number: NCT04034095

Locations: 🇯🇵
Akita University Hospital, Akita, Japan
🇯🇵
Juntendo University Hospital, Bunkyo Ku, Japan
🇯🇵
Tokyo Medical and Dental University Hospital, Bunkyo Ku, Japan

and more 74 locations

INTREPId (INTermediate Risk Erection PreservatIon Trial)

Phase 2

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: Bicalutamide
Drug: Darolutamide
Drug: GnRH Agonist
Radiation: Radiation Therapy

First Posted Date: 2019-07-18

Last Posted Date: 2025-04-09

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 234

Registration Number: NCT04025372

Locations: 🇺🇸
Stamford Hospital, Stamford, Connecticut, United States
🇺🇸
Beth Israel Deaconness Medical Center, Boston, Massachusetts, United States
🇺🇸
Brigham and Women Hospital, Boston, Massachusetts, United States

and more 8 locations

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1

Terminated

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Anatomic Stage IV Breast Cancer AJCC v8
Anemia
Ann Arbor Stage III Hodgkin Lymphoma
Ann Arbor Stage III Non-Hodgkin Lymphoma
Ann Arbor Stage IV Hodgkin Lymphoma
Ann Arbor Stage IV Non-Hodgkin Lymphoma
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Castration-Resistant Prostate Carcinoma

Interventions: Drug: Abemaciclib
Drug: Abiraterone
Drug: Afatinib
Biological: Bevacizumab
Drug: Bicalutamide
Procedure: Biospecimen Collection
Drug: Bortezomib
Drug: Cabazitaxel
Drug: Cabozantinib
Drug: Capecitabine
Drug: Carboplatin
Drug: Celecoxib
Drug: Cobimetinib
Drug: Copanlisib
Drug: Dabrafenib
Drug: Dacomitinib
Drug: Darolutamide
Drug: Dasatinib
Drug: Doxorubicin
Biological: Durvalumab
Drug: Enasidenib
Drug: Entrectinib
Drug: Enzalutamide
Drug: Erlotinib
Drug: Everolimus
Drug: Fluorouracil
Drug: Idelalisib
Drug: Imatinib
Biological: Ipilimumab
Drug: Lenvatinib
Drug: Leucovorin
Drug: Lorlatinib
Drug: Losartan
Drug: Nab-paclitaxel
Drug: Neratinib
Biological: Nivolumab
Drug: Olaparib
Drug: Oxaliplatin
Drug: Palbociclib
Drug: Panobinostat
Biological: Pembrolizumab
Biological: Pertuzumab
Drug: Ponatinib
Other: Quality-of-Life Assessment
Drug: Regorafenib
Drug: Ruxolitinib
Drug: Sirolimus
Drug: Sorafenib
Drug: Sunitinib
Drug: Trametinib
Biological: Trastuzumab Emtansine
Drug: Tretinoin
Drug: Vemurafenib
Drug: Venetoclax
Drug: Vismodegib
Drug: Vorinostat

First Posted Date: 2019-03-18

Last Posted Date: 2024-03-04

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 2

Registration Number: NCT03878524

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery

Phase 2

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Radiation: Radiation Therapy
Drug: Bicalutamide
Drug: Enzalutamide
Drug: GnRH analog

First Posted Date: 2019-01-18

Last Posted Date: 2024-10-16

Lead Sponsor: RTOG Foundation, Inc.

Target Recruit Count: 188

Registration Number: NCT03809000

Locations: 🇺🇸
USC Medical Center - Los Angeles County, Los Angeles, California, United States
🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸
Sutter Roseville Medical Center, Roseville, California, United States

and more 105 locations

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Phase 3

Recruiting

Conditions: Castration Levels of Testosterone
Metastatic Prostatic Adenocarcinoma
Stage IV Prostate Cancer AJCC v8
Stage IVA Prostate Cancer AJCC v8
Stage IVB Prostate Cancer AJCC v8

Interventions: Drug: Abiraterone
Drug: Bicalutamide
Drug: Degarelix
Drug: Flutamide
Drug: Docetaxel
Drug: Goserelin Acetate
Drug: Histrelin Acetate
Drug: Leuprolide Acetate
Drug: Nilutamide
Procedure: Orchiectomy
Other: Quality-of-Life Assessment
Radiation: Radiation Therapy
Drug: Prednisone
Procedure: Radical Prostatectomy
Drug: Triptorelin

First Posted Date: 2018-09-19

Last Posted Date: 2024-08-16

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 1273

Registration Number: NCT03678025

Locations: 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Parkland Memorial Hospital, Dallas, Texas, United States
🇺🇸
UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States

and more 335 locations

Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients

Phase 2

Active, not recruiting

Conditions: Breast Neoplasm Female
Breast Cancer
Breast Carcinoma
Breast Tumor

Interventions: Drug: Nivolumab
Drug: Ipilimumab
Drug: Bicalutamide

First Posted Date: 2018-08-29

Last Posted Date: 2025-03-10

Lead Sponsor: Providence Health & Services

Target Recruit Count: 30

Registration Number: NCT03650894

Locations: 🇺🇸
Providence Oncology & Hematology Care Clinic - Eastside, Portland, Oregon, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery

Phase 2

Conditions: Prostate Cancer
High-risk Prostate Cancer

Interventions: Drug: HSV-Tk
Drug: Valacyclovir
Drug: Bicalutamide
Drug: Leuprolide Acetate
Radiation: Brachytherapy, External beam radiotherapy
Procedure: Radical prostatectomy

First Posted Date: 2018-05-31

Last Posted Date: 2021-04-06

Lead Sponsor: The Methodist Hospital Research Institute

Target Recruit Count: 60

Registration Number: NCT03541928

Locations: 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States

A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate Cancer

Phase 3

Active, not recruiting

Conditions: Prostate Cancer
Hormone-Dependent Prostate Cancer

Interventions: Drug: SHR3680
Drug: Bicalutamide

First Posted Date: 2018-05-09

Last Posted Date: 2021-03-02

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 654

Registration Number: NCT03520478

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, China
🇧🇬
Complex oncological center - Bourgas, Burgas, Bulgaria
🇧🇬
MHAT - Dobrich. AD, Dobrich, Bulgaria

and more 64 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy